However, in participants ≥70 years of age, we observed possible evidence of efficacy of MitoQ supplementation for improving select measures of strength. Future clinical trials with MitoQ and possibly other mitochondria-targeted antioxidant approaches for enhancing physical function with ageing should focus on older adults of more advanced age or more frail clinical populations.

P2, N=33, Completed, University of Minnesota | Recruiting --> Completed | N=50 --> 33

P=N/A, N=0, Withdrawn, University-Town Hospital of Chongqing Medical University | N=38646 --> 0 | Completed --> Withdrawn

P1/2, N=25, Not yet recruiting, University of Arizona

P=N/A, N=86, Not yet recruiting, Colorado State University

P1, N=10, Not yet recruiting, University of Texas Southwestern Medical Center

Postoperatively, the patient received adjuvant chemotherapy with the AIM (doxorubicin, ifosfamide, and mesna) regimen. Given the extreme rarity of PRSS, we discuss the diagnostic challenges, molecular characteristics, and treatment approach adopted at our institution, contributing to the limited but growing body of knowledge on this rare entity.

P4, N=216, Not yet recruiting, Xuanwu Hospital Capital Medical University; Xuanwu Hospital Capital Medical University

P=N/A, N=10, Recruiting, Erasme University Hospital

P1, N=44, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Feb 2030 --> Jan 2031 | Trial primary completion date: Feb 2030 --> Jan 2031

P2, N=120, Completed, Faraday Pharmaceuticals, Inc. | Phase classification: P2a --> P2

P2, N=79, Active, not recruiting, University of Edinburgh | Recruiting --> Active, not recruiting | N=206 --> 79 | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Dec 2024 --> Dec 2025